Patch-Testing for the Management of Hypersensitivity Reactions to Second-Line Anti-Tuberculosis Drugs: A Case Report by Khan, S et al.
Patch-testing for the management of 
hypersensitivity reactions to second-line anti-
tuberculosis drugs: a case report 
Samsuddin Khan1 
Email: samsuddinik@gmail.com 
Aristomo Andries1 
Email: msfocb-mumbai-med@brussels.msf.org 
Asha Pherwani2 
Email: ashadr42@hotmail.com 
Peter Saranchuk3 
Email: peter.saranchuk@joburg.msf.org 
Petros Isaakidis1* 
*
 Corresponding author 
Email: msfocb-asia-epidemio@brussels.msf.org 
1
 Médecins Sans Frontières, Chandni Bungalow, Union Park, Off Carter Road, 
Khar (W), Mumbai 400 052, India 
2
 Allergy Immunology Department, P.D. Hinduja Hospital Research Center, 
Mumbai, India 
3
 Southern Africa Medical Unit (SAMU), Médecins Sans Frontières, Cape Town, 
South Africa 
Abstract 
Background 
The second-line anti-tuberculosis drugs used in the treatment of multidrug-resistant 
tuberculosis often cause adverse events, especially in patients co-infected with the human 
immunodeficiency virus. Severe hypersensitivity reactions due to these drugs are rare and 
there is little published experience to guide their management. 
Case presentation 
A 17-year old Indian female multidrug-resistant tuberculosis patient co-infected with human 
immunodeficiency virus developed a hypersensitivity reaction after starting second-line anti-
tuberculosis treatment in Mumbai, India. The patient was being treated with kanamycin, 
moxifloxacin, para-aminosalicylic acid, cycloserine, clofazimine, and amoxicillin-clavulanic 
acid. Twenty-four hours later, the patient developed generalized urticaria, morbilliform rash 
and fever. All drugs were suspended and the patient was hospitalised for acute management. 
Skin patch-testing was used to identify drugs that potentially caused the hypersensitivity 
reaction; results showed a strong reaction to clofazimine, moderate reaction to kanamycin 
and mild reaction to cycloserine. An interim second-line anti-tuberculosis regimen was 
prescribed; cycloserine and kanamycin were then re-challenged one-by-one using 
incremental dosing, an approach that allowed clinicians to re-introduce these drugs promptly 
and safely. The patient is currently doing well. 
Conclusions 
This is the first case-report of a multidrug-resistant tuberculosis patient co-infected with the 
human immunodeficiency virus with hypersensitivity reaction to multiple second-line anti-
tuberculosis drugs. Skin patch-testing and controlled re-challenge can be a useful 
management strategy in such patients. There is an urgent need for second-line anti-
tuberculosis regimens that are more effective, safe and better tolerated. 
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Background 
The management of patients with multidrug-resistant tuberculosis (MDR-TB), defined as 
resistance to isoniazid and rifampicin, is onerous, particularly in those co-infected with the 
human immunodeficiency virus (HIV) [1,2]. The second-line anti-TB drugs used in MDR-TB 
treatment regimens frequently cause adverse events (AE) [3]. Severe hypersensitivity 
reactions such as anaphylaxis are rare but do occur with these drugs [4]. In case of a severe 
AE, the culprit drug must be substituted with another drug if available. However, several 
drugs in the treatment regimen may be responsible for a severe AE, including 
hypersensitivity reaction, making timely identification of the culprit drug(s) and substitution 
challenging. Substituting all possible culprit drugs in such cases is not possible due to the 
limited number of drugs currently available to treat MDR-TB [4]. 
Skin patch-testing has traditionally been used to identify agents involved in type I and type 
IV hypersensitivity reactions. Type I hypersensitivity is an immediate immune reaction to an 
antigen, typically involving mast cells and basophil degranulation, which release 
inflammatory mediators and cause hives, redness, and angioedema; such symptoms are 
referred to as anaphylactic reaction. Type IV hypersensitivity is a delayed-type 
hypersensitivity reaction which can take more than 12 hours to develop. This reaction 
involves sensitized T memory cells that respond with stronger immune reaction to subsequent 
exposure with the same antigen. Type IV hypersensitivity is observed in contact dermatitis 
which is characterized by rash [5]. 
In this case report we describe our experience with the use of patch-testing to manage 
hypersensitivity reaction due to multiple drugs in a MDR-TB patient co-infected with HIV 
being treated with second-line anti-TB drugs and antiretroviral therapy (ART). 
Case presentation 
A 17-year old Indian female was diagnosed with HIV infection in January 2011 in a public 
ART centre. Her baseline CD4 cell count at the time of diagnosis was 428 cells/mm3. The 
patient was not initiated on ART at baseline as the national HIV program in India has a 
threshold of 350 cells/mm3 for ART enrollment in adolescent and adult patients [6]. Co-
trimoxazole preventive therapy was initiated when the patient’s CD4 count fell to 340 
cells/mm3 in February 2013, nevertheless, ART was not initiated at that time. 
The patient was diagnosed with pulmonary MDR-TB in June 2013 and referred to the 
Médecins Sans Frontières (MSF) project. She was treated for pulmonary tuberculosis one 
year earlier by a private practitioner with first-line anti-TB treatment regimen consisting of 
isoniazid, rifampicin, pyrazinamide and ethambutol, plus the addition of ofloxacin. The drug 
susceptibility test (DST) result to this second episode of TB showed resistance of the of the 
Mycobacterium tuberculosis strain to isoniazid, rifampicin, ethambutol, pyrazinamide, 
streptomycin, ofloxacin and ethionamide. Peripheral full blood count (FBC), including a 
differential white cell count, creatinine, alanine aminotransferase (ALT), and potassium were 
performed as baseline tests prior to initiation of drug-resistant TB treatment and found to be 
normal. The CD4 count at the time of enrollment in the MSF project was 205 cells/mm3 and 
the HIV viral load result was 29,420 copies/ml. The patient’s weight on admission was 40.3 
Kg. There was no history of allergic reactions. 
After counselling the patient and caregiver, and identifying a health care worker to directly 
observe therapy (i.e. a DOT provider), an individualized regimen was devised, based on the 
DST result. The regimen contained capreomycin, moxifloxacin, para-aminosalicylic acid 
(PAS), cycloserine, amoxicillin/clavulanic acid (amoxiclav) and clofazimine. ART was to be 
initiated within 14 to 30 days after anti-TB treatment initiation, after the patient was found to 
be tolerating the anti-TB treatment. 
However, twenty-four hours after TB treatment initiation, the patient developed generalised 
urticarial and morbilliform rash, fever, angioedema, laryngospasm, and dyspnoea. She was 
immediately referred and admitted to a hospital. All drugs were suspended. During 
admission, the symptoms and signs of the hypersensitivity reaction subsided. The patient was 
observed for 48 hours for any late hypersensitivity reaction and then was discharged. The 
FBC, liver function, and renal function tests did not show any abnormality. 
To help identify the drug(s) responsible for the hypersensitivity reaction, a careful re-
challenge plan was made. The following 4-step strategy was used to manage the patient’s 
hypersensitivity reaction related to second-line anti-TB drugs: 
Step 1: Skin patch-testing 
The patient was referred to a specialized clinic for skin patch-testing one week following the 
anaphylactic episode and after antihistamine medication had been stopped. The patch-testing 
included the following drugs: PAS, moxifloxacin, amoxiclav, cycloserine, kanamycin, 
clofazimine, and cotrimoxazole. The test showed an extremely positive reaction (+3) to 
clofazimine, strongly positive reaction (+2) to kanamycin and weakly positive reaction (+1) 
to cycloserine. No reaction was observed to moxifloxacin, amoxiclav, PAS, and 
cotrimoxazole. We decided to permanently suspend the use of clofazimine and to re-
challenge with cycloserine and kanamycin. 
Step 2: Introduction of an interim MDR-TB treatment regimen 
We initiated the patient on an interim MDR-TB treatment regimen consisting of drugs that 
were less likely to cause hypersensitivity reactions. This regimen included moxifloxacin 400 
mg OD, PAS 9.2 gram divided in two doses/day, amoxiclav 625 mg TD, linezolid 600 mg 
OD and clarithromycin 500 mg BD. The first doses were given under direct observation at 
the clinic. We observed the patient for 2 hours after administration of the medication and 
discharged her with no new symptoms or signs. The interim regimen was continued for one 
week. The patient underwent testing at the end of the week consisting of a FBC, ALT, and 
serum creatinine. The FBC was unremarkable: hemoglobin (Hb) was 11.4 g/dL, platelets 
were 150,000 /µL, and the white cell count was 4100 /µL, with a differential of 48% 
neutrophils, 43% lymphocytes, and 1% eosinophils. ALT was 54.6 U/L and serum creatinine 
was 0.7 mg/dL (creatinine clearance was 82.98 ml/min). 
Step 3: Re-challenge with drugs having moderate and mild skin-patch test 
results 
The patient was admitted to the hospital for twelve days for re-challenging with cycloserine 
and kanamycin. Cycloserine was started on Day 1 in escalating dosages as shown in the 
Table 1. 
Table 1 Re-challenge dose of cycloserine and kanamycin 
Prescribed medicine Day 1 Day 2 Day 3 Day 4 Day 5-7 Remarks 
Cycloserine (mg) 12.5 OD 62.5 OD 125 OD 250 OD 250 BD No reactions 
Prescribed medicine Day 8 Day 9 Day 10 Day 11 Day 12 Remarks 
Kanamycin (mg) 12.5 OD 62.5 OD 125 OD 300 OD 600 OD No reactions 
OD = once daily; BD = twice daily; TD = three times/day. 
Since the patient tolerated both cycloserine and kanamycin, the MDR-TB treatment regimen 
was then modified as follows: kanamycin 600 mg 6 days per week, moxifloxacin 400 mg 
(OD), cycloserine 500 mg (OD), PAS 9.2 gram (BD), linezolid 600 mg (OD), and amoxiclav 
625 mg (TD). 
Step 4: Introduction of prophylaxis for opportunistic infections and 
antiretroviral therapy 
Two weeks after the MDR-TB treatment regimen was modified and once we confirmed that 
it was well tolerated, cotrimoxazole prophylaxis was re-initiated to help prevent other 
opportunistic infections. Two weeks later, we initiated antiretroviral therapy consisting of 
tenofovir, lamivudine and efavirenz. The patient tolerated the cotrimoxazole and 
antiretrovirals very well. 
The patient’s sputum quickly converted, with the acid fast bacilli (AFB) and culture results 
becoming negative one month after initiation of the anti-TB regimen. The culture for M. 
tuberculosis remained negative up to the time of reporting this study. Two months after ART 
initiation, the HIV-1 viral load became undetectable and the CD4 count had increased to 485 
cells/mm3. The patient was clinically stable, with no medical complaints on the last 
appointment before reporting of this study, and no symptoms of hypersensitivity reaction. 
Discussion 
Hypersensitivity reactions to second-line anti-TB drugs are rare but not completely unknown. 
There are limited reports available about hypersensitivity to PAS and ethionamide as second-
line medicines commonly used in MDR-TB regimen [7-9]. In other studies, the same two 
second-line anti-TB medicines were associated with hepatotoxicity, while fluoroquinolones 
and cycloserine were mentioned to have a lower risk for hepatotoxicity [10,11]. These studies 
did not describe hypersensitivity reactions associated with other anti-TB medicines that are 
commonly added in patients with M. tuberculosis strains resistant to aminoglycosides and/or 
fluoroquinolones: clofazimine, linezolid, and amoxicillin-clavulanic acid. Hypersensitivity 
can manifest from symptoms suc h as rash and pruritus to severe reactions such as Drug 
Reaction with Eosinophilia and Systemic Symptoms (DRESS), anaphylaxis, Stevens-Johnson 
Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [4]. 
Patch-testing is a diagnostic procedure that is most commonly used for identifying the 
possible causes of contact dermatitis, which is a type IV hypersensitivity reaction. Patch-
testing can also be used in the investigation of type I hypersensitivity reactions and in DRESS 
syndrome (type IVb hypersensitivity reaction) [5,12]. If done properly, the test has good 
sensitivity, specificity, accuracy and relevance. The procedure involves mixing the allergen to 
be tested with white petrolatum (i.e. the vehicle) and applied in close proximity with the skin. 
The first reading is taken after 30 minutes to look for type 1 hypersensitivity reaction, while a 
second reading is taken after 48 hours to investigate for type 4 delayed hypersensitivity 
reaction. Between the 2 readings, the patient should be instructed not to wet, rub or scratch 
the testing area, avoid exercise and sweating. Patch test readings are evaluated using the 
International Contact Dermatitis Research Group (ICDRG) grading system: ‘-‘stands for 
negative, ‘+’ stands for a weak (non-vesicular) positive reaction, ‘++’ stands for a strong 
(vesicular) positive reaction and ‘+++’ stands for extreme (bullous) positive reaction. In 
general, the accuracy of patch-testing in determining the cause when there is a weakly 
positive reaction is 20%-50%, compared to 80%-90% with a strong reaction and 95%-100% 
with an extreme positive reaction. If patch testing is not done properly, there are high chances 
of false positive and false negative results [13]. 
In MDR-TB patients co-infected with HIV, early anti-TB treatment initiation with an 
effective regimen is essential, as pre-treatment mortality among these patients is high [14,15]. 
Identifying the drugs least likely to have caused the hypersensitivity reaction is important, as 
it allows clinicians to design and introduce an individualized regimen that can be started as 
soon as the person is clinically stable. Use of an interim MDR-TB regimen allows treatment 
to be continued while the clinician investigates and determines the most likely culprit drug. 
In this case, we did not re-challenge the patient with the drug having an extremely strong 
positive reaction on patch-testing, clofazimine. Instead of re-challenging with clofazimine, 
we administered linezolid, a group-5 anti –TB drug that was already being given in the 
interim regimen (2). We opted to re-challenge with only those anti-TB drugs having less 
strong skin-patch test results, and this was done in ascending order of suspicion, i.e. the drug 
with the mild reaction (cycloserine) before the one with the stronger reaction (kanamycin). 
Introduction of cotrimoxazole prophylaxis and antiretroviral therapy (ART) are important to 
further reduce the risk of morbidity and mortality in co-infected patients. ART initiation is 
usually postponed for several weeks after anti-TB treatment to reduce the risk of immune 
reconstitution inflammatory syndrome (IRIS) [16]. However, ART should not be excessively 
delayed, as doing so increases the risk of mortality [16]. 
Guidelines are currently lacking on management of patients experiencing allergic reactions to 
multiple second-line anti-TB drugs. There are no evidence-based recommendations or expert 
opinions on how to design an interim regimen and how best to re-challenge possible culprit 
drugs, including their optimal sequence, dosage and timing schemes. Current guidance tends 
to be limited to the management of non-anaphylactic allergic reactions [4], management of 
hepatitis due to first-line (but not second-line) anti-TB drugs or anaphylactic reactions [11], 
as well as case reports on the management of allergic reactions in patients on first-line anti-
TB treatment [17]. 
Conclusions 
To our knowledge this is the first case report of an HIV/MDR-TB co-infected patient with 
hypersensitivity reactions to multiple second-line anti-TB drugs. Our experience showed that 
skin-patch testing and timed re-challenging was a useful part of the management strategy in a 
MDR-TB patient co-infected with HIV having allergic reactions to multiple second-line anti-
TB drugs. By utilizing skin-patch testing, we managed to identify certain anti-TB medicines 
that were less likely to be the cause of the hypersensitivity reaction and keep them in the 
post-reaction interim regimen. Similar to the management of hypersensitivity when seen with 
first-line anti-TB medicines, an interim regimen is important to prevent further resistance 
against anti-TB medicines [11]. Instead of re-challenging all six anti-TB medicines one-by-
one, which could require a total of 42 days, we were able to safely identify anti-TB medicines 
that did not require re-challenge by utilizing skin-patch testing, and by doing so shortened the 
time of the re-challenge process by half. 
The entire process might have been avoided if a simpler regimen existed to treat MDR-TB. 
There is an ongoing and urgent need for MDR-TB treatment regimens that are more 
effective, better tolerated, and consisting of fewer medicines. 
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